Effective this month, the coverage applies to approximately 70% of all United Healthcare commercial lives.
United Healthcare has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on the company’s commercial formularies, Kala Pharmaceuticals announced on Tuesday.
Effective this month, the coverage applies to approximately 70% of all commercial lives — 118 million individuals, according to a news release.
Further, Cigna Medicare has also added EYSUVIS as a preferred brand, effective February 2022, Kala stated. With this latest addition, EYSUVIS has coverage via Medicare for select plans with Express Scripts, Prime Therapeutics, and Cigna — totaling 15% of all Medicare lives.
EYSUVIS became commercially available in January 2021. It is the first and only FDA-approved medicine for short-term treatment of the signs and symptoms of dry eye.